Skip to main content

Advertisement

Table 6 Treatment-emergent adverse events occurring in ≥10% of patients in phase 2 (n = 31)

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Treatment-emergent AEs, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Any grade
Diarrhea 14 (45.2) 9 (29.0) 5 (16.1) 0 28 (90.3)
Fatigue 2 (6.5) 11 (35.5) 4 (12.9) 1 (3.2) 18 (58.1)
Nausea 9 (29.0) 6 (19.4) 1 (3.2) 0 16 (51.6)
Edema peripheral 6 (19.4) 5 (16.1) 1 (3.2) 0 12 (38.7)
Vomiting 7 (22.6) 3 (9.7) 1 (3.2) 0 11 (35.5)
Abdominal pain 3 (9.7) 3 (9.7) 3 (9.7) 0 9 (29.0)
Insomnia 7 (22.6) 2 (6.5) 0 0 9 (29.0)
Pruritus 4 (12.9) 4 (12.9) 1 (3.2) 0 9 (29.0)
Pain in extremity 5 (16.1) 2 (6.5) 0 1 (3.2) 8 (25.8)
Night sweats 4 (12.9) 3 (9.7) 0 0 7 (22.6)
Anemia 0 1 (3.2) 3 (9.7) 2 (6.5) 6 (19.4)
Bone pain 1 (3.2) 1 (3.2) 4 (12.9) 0 6 (19.4)
Asthenia 4 (12.9) 1 (3.2) 0 0 5 (16.1)
Constipation 5 (16.1) 0 0 0 5 (16.1)
Dyspnea 4 (12.9) 0 1 (3.2) 0 5 (16.1)
Cardiac murmur 0 4 (12.9) 0 0 4 (12.9)
Hyperuricemia 2 (6.5) 0 0 2 (6.5) 4 (12.9)
Pyrexia 4 (12.9) 0 0 0 4 (12.9)
Rash 2 (6.5) 1 (3.2) 1 (3.2) 0 4 (12.9)
Upper respiratory tract infection 3 (9.7) 1 (3.2) 0 0 4 (12.9)
Weight decreased 4 (12.9) 0 0 0 4 (12.9)